Organon & Co. (NYSE:OGN) Sets New 12-Month Low - Should You Sell?
Organon & Co. (NYSE:OGN) has reached a new 52-week low of $13.18, down from a previous close of $14.45. Analysts have mixed ratings, with Morgan Stanley lowering its target price to $16.00 and Barclays reducing it to $24.00. The stock has an average rating of "Hold" and a target price of $20.80. The company reported Q4 earnings of $0.83 EPS, missing estimates, and declared a quarterly dividend of $0.28. Institutional investors hold 77.43% of the stock, indicating strong interest despite recent price declines.
Organon & Co. (NYSE:OGN - Get Free Report)'s stock price reached a new 52-week low on Friday . The stock traded as low as $13.25 and last traded at $13.18, with a volume of 785212 shares. The stock had previously closed at $14.45.
Get Organon & Co. alerts:
Wall Street Analyst Weigh In
- Merck, the Dow's hottest stock, gets set to report Q4 financials
Several research analysts recently issued reports on the company. Morgan Stanley lowered their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Finally, Barclays decreased their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $20.80.
Read Our Latest Stock Report on Organon & Co.
Organon & Co. Trading Down 9.6 %
- Lululemon Athletica Races to New High with S&P 500 Entry
The firm's 50-day simple moving average is $15.22 and its 200-day simple moving average is $16.10. The firm has a market capitalization of $3.37 billion, a PE ratio of 3.92, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.
Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.
Organon & Co. Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 8.57%. Organon & Co.'s payout ratio is currently 33.63%.
Institutional Trading of Organon & Co.
Institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new stake in Organon & Co. in the third quarter worth about $113,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Organon & Co. by 8.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 55,506 shares of the company's stock valued at $1,062,000 after purchasing an additional 4,298 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Organon & Co. by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 836,389 shares of the company's stock valued at $16,000,000 after buying an additional 4,029 shares in the last quarter. Verition Fund Management LLC bought a new position in Organon & Co. in the 3rd quarter worth $195,000. Finally, Paloma Partners Management Co bought a new position in shares of Organon & Co. in the third quarter worth about $362,000. Hedge funds and other institutional investors own 77.43% of the company's stock.
Organon & Co. Company Profile
(Get Free Report)Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
- Five stocks we like better than Organon & Co.
- Insider Buying Explained: What Investors Need to Know
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- What to Know About Investing in Penny Stocks
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Investing in Construction Stocks
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Organon & Co. Right Now?
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
